Anavex Life Sciences Corp.
General ticker "AVXL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $788.2M (TTM average)
Anavex Life Sciences Corp. follows the US Stock Market performance with the rate: 1.8%.
Estimated limits based on current volatility of 3.1%: low 4.04$, high 4.49$
Factors to consider:
- Total employees count: 42 as of 2024
- Top business risk factors: Operational and conduct risks, Product development risks, Third-party risks, Regulatory and compliance, Market competition
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-09-30 to 2026-09-30
- 2024-09-30 to 2025-09-30 estimated range: [3.86$, 8.89$]
- 2025-09-30 to 2026-09-30 estimated range: [3.43$, 8.08$]
Financial Metrics affecting the AVXL estimates:
- Positive: with PPE of -10.7 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -6.60 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of -100 <= -0.75
- Positive: Investing cash flow per share per price, % of 0 > -0.66
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 88.71 > 63.39
Short-term AVXL quotes
Long-term AVXL plot with estimates
Financial data
| YTD | 2022-09-30 | 2023-09-30 | 2024-09-30 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $50.99MM | $55.76MM | $52.88MM |
| Operating Income | $-50.99MM | $-55.76MM | $-52.88MM |
| Non-Operating Income | $3.37MM | $8.26MM | $9.88MM |
| R&D Expense | $37.92MM | $43.72MM | $41.84MM |
| Income(Loss) | $-47.62MM | $-47.50MM | $-43.00MM |
| Taxes | $0.36MM | $0.01MM | $0.00MM |
| Profit(Loss)* | $-47.98MM | $-47.51MM | $-43.00MM |
| Stockholders Equity | $142.49MM | $141.85MM | $120.26MM |
| Assets | $152.71MM | $154.39MM | $135.57MM |
| Operating Cash Flow | $-24.24MM | $-27.79MM | $-30.81MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $21.29MM | $29.65MM | $11.97MM |
| Earnings Per Share** | $-0.62 | $-0.60 | $-0.52 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.